Breast cancer is the most common cancer among women all over the world. It affects both men and women, but it is more prevalent in women. Early detection, a more customised approach to advance therapy, and a better understanding of the disease have all contributed to increased survival rates and a steady decline in the number of deaths linked with this disease. It is critical to raise awareness about the dangers, symptoms, and treatment of breast cancer. In the fields of medicine and diagnosis, new procedures are being introduced all around the world.
Doctors can utilise information about a patient's own genes or tumour mutations to help diagnose and treat cancer with precision medicine. Precision medicine aids in determining whether particular targeted medicines and immunotherapy will be effective in the treatment of a patient who has been diagnosed with breast cancer. Knowing this enables for a more proactive approach to early detection, such as more frequent and better screening tests.
Why to attend
It will also give an overview of new inventions and processes. Because it provides expertise in the field, it is very valuable for students, physicians, nurses, doctors, health care workers, and academics will benefit greatly from face-to-face meetings with scientists and senior lecturers at this conference. It also allows learning about their market competitors.
Benefits
Accepted abstracts will be published in Journal of Cancer Science & Therapy and provided with DOI Global networking: In transferring and exchanging Ideas. A Unique Opportunity for Advertisers and Sponsors at this International event.
Target Audience
Radiologist
Radiation Oncologist
Radiation Therapist
Medical Oncologist
Breast Care Nurse
Surgeon
Reconstructive (plastic) Surgeon
Lymphoedema Therapist
Breast Cancer Surgeons, pathologists
Nurse Practitioners/Nurses
Healthcare Faculty
Medical Colleges
Healthcare Associations and Societies
Business Entrepreneurs
Training Institutes
Manufacturing Medical Devices Companies
Data Management Companies
The Global Breast Cancer Drugs Market research offers a comprehensive analysis of the industry. The research provides a detailed analysis of key market segments, trends, drivers, constraints, the competitive landscape, and other important market variables. The market for breast cancer drugs was worth USD 15.41 billion in 2020 and is expected to increase to USD 31.1 billion by 2028, with a CAGR of 9.12% from 2021 to 2028. Patients with breast cancer are also at a higher risk of contracting COVID-19. Continued efforts to ensure a quick return to screening and avoid delays in evaluating symptomatic women can considerably mitigate the effects of the initial pandemic-related suspensions.
Associations and societies:
American Cancer Society
American Medical Women's Association
American Society for Radiation Oncology
American Society of Paediatric Hematology/Oncology
Association of Cancer Physicians
Association of Chartered Physiotherapists in Women’s Health
Association of Women's Health, Obstetric and Neonatal Nurses
Breast Screen Australia Program
Cancer Relief Society Nepal
Cancer Society of Finland
Cancer Society of New Zealand
Caribbean Women's Health Association
European Association for Cancer Research (EACR)
Indonesian Society of Gynecologic Oncology
International Association for Women's Mental Health
International Gynecologic Cancer Society
Iranian Society of Radiation Oncology
Japanese Breast Cancer Society
New Zealand Breast Cancer Foundation (NZBCF)
Society for Women's Health Research
Spanish Association for Cancer Research (CMA)
Thai Gynecologic Cancer Society
